Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety
Pediatric Dermatology · 2026
DOI: 10.1111/pde.70298 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pediatric Dermatology, 2026. Verfasst von Aditi Chokshi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Pyrazoles. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a common inflammatory skin disease affecting up to 20% of children. Long‐term topical management is often limited by safety concerns, tolerability issues, and caregiver hesitancy. Topical janus kinase (JAK) inhibitors have emerged as targeted nonsteroidal therapies, with recent pediatric approval of ruxolitinib expanding treatment options. This systematic review synthesizes pediatric‐only evidence on topical JAK inhibitors for AD, focusing on efficacy, safety, and treatment strategies for clinical practice.
Methods
A PRISMA‐guided systematic review of PubMed, Embase, Web of Science, and ClinicalTrials.gov was conducted through November 2025. Eight studies met inclusion criteria, encompassing 541 pediatric patients treated with ruxolitinib or delgocitinib.
Results
Across randomized and extension studies, both agents produced rapid, clinically meaningful improvements in both disease severity and pruritus, with benefits observed within the first several weeks of treatment. Ruxolitinib showed consistent efficacy in patients with both limited and extensive disease involvement, while delgocitinib showed sustained disease control with continuous use, including in younger children and infants. Topical JAK inhibitors were generally well tolerated, with adverse event rates comparable to vehicle and few discontinuations. Application‐site reactions were uncommon, and no treatment‐related serious AEs were reported.
Conclusions
Overall, available pediatric data supports topical JAK inhibitors as effective and well‐tolerated nonsteroidal options for AD, providing rapid symptom relief and disease control that may help expand steroid‐sparing treatment options for children.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA.
- Department of Dermatology, St. John's Episcopal Hospital, Far Rockaway, New York, USA.
- The Dermatology Specialists, New York, New York, USA.
- SINY Dermatology, Brooklyn, New York, USA.
- The Ronald O. Perelman Department of Dermatology, NYU Langone Health Hospital, Brooklyn, New York, USA.
ORCID-Profile: Aditi Chokshi
Zitieren
APA
Chokshi, A., Keelin, J., Foy, V., Choudhury, S., & Fischer, D. (2026). Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety. Pediatric Dermatology. https://doi.org/10.1111/pde.70298
Vancouver
Chokshi A, Keelin J, Foy V, Choudhury S, Fischer D. Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety. Pediatric Dermatology. 2026. doi:10.1111/pde.70298
BibTeX
@article{Chokshi2026,
author = {Chokshi, Aditi and Keelin, Jennifer and Foy, Valerie and Choudhury, Sourab and Fischer, Daniel},
title = {Topical Janus Kinase Inhibitors for Pediatric Atopic Dermatitis: A Systematic Review of Efficacy and Safety},
journal = {Pediatric Dermatology},
year = {2026},
doi = {10.1111/pde.70298}
}
EUVIMED